RxDoctor Payments Data

Megan Hyland, MD

Neurology · Rochester, NYNPI 1588778955

Payments from drug & device makers

$608,661in general payments, 2019–2025

Across 23 payments — averaging $26,464 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$609K

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen23$608,661

How this compares

$608,661 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$10,423
Medicare patients
80
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide120$285,779
TecfideraDimethyl Fumarate25$263,344
CopaxoneGlatiramer Acetate45$248,980
Kesimpta PenOfatumumab26$223,680
Rebif RebidoseInterferon Beta-1a/Albumin18$205,277
RebifInterferon Beta-1a/Albumin21$204,448
GilenyaFingolimod Hcl18$189,517
Avonex Pen (4 Pack)Interferon Beta-1a18$177,710
Avonex (4 Pack)Interferon Beta-1a20$176,369
Dalfampridine ErDalfampridine187$148,467
Glatiramer Acetate45$105,843
AubagioTeriflunomide11$101,155
GlatopaGlatiramer Acetate26$64,982
FingolimodFingolimod Hcl34$48,689
Dimethyl Fumarate47$36,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$608,661$439,71345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →